Oric Pharmaceuticals, Inc. Common Stock

ORIC trades at a $0.9B market cap with an astonishing 21.42% short interest—nearly a quarter of float—suggesting significant skepticism from institutional bears. The RSI of 40.3 indicates neither oversold nor overbought conditions, landing in neutral territory, while the stock trades well below its 52-week high with no meaningful P/E ratio, implying unprofitability or losses. This combination of heavy short exposure, modest valuation size, and depressed positioning relative to recent peaks creates classic squeeze dynamics: if clinical data or catalysts shift sentiment, the compressed short position could trigger rapid repricing. The lack of earnings and the biotech sector's inherent volatility make this a speculative situation driven by pipeline narrative rather than fundamental earnings power.